跳转至内容
Merck
CN

L8533

Sigma-Aldrich

兰索拉唑

≥98% (TLC), powder

登录查看公司和协议定价

经验公式(希尔记法):
C16H14F3N3O2S
分子量:
369.36
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (TLC)

形式

powder

颜色

off-white

创始人

Novartis

储存温度

2-8°C

SMILES字符串

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

胃质子泵抑制剂。

特点和优势

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

T B Bödvarsdóttir et al.
Diabetologia, 53(10), 2220-2223 (2010-06-30)
Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus.
Lin Ye et al.
Journal of cellular and molecular medicine, 25(5), 2703-2713 (2021-02-20)
Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for gastrointestinal complications in cancer patients, have been reported to cause adverse
Sayed M Derayea et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 209, 209-216 (2018-11-07)
Cytochrome P450 (CYP) is a class of heme-containing enzymes which mainly catalyze a monooxygenation reaction of various chemicals, and hence CYP plays a key role in the drug metabolism. Although CYP2C19 isoform is a minor hepatic CYP, it metabolizes clinically
L B Barradell et al.
Drugs, 44(2), 225-250 (1992-08-01)
Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus. Results of short term (less than 8 weeks) clinical
D A Peura et al.
Alimentary pharmacology & therapeutics, 37(8), 810-818 (2013-03-05)
Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. To assess the impact of BMI on baseline heartburn symptom severity

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门